Business Context and Reporting Period
Company: Editas Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2017
Event: Entry into a Material Definitive Agreement (Strategic Alliance and Option Agreement) with Allergan Pharmaceuticals International Limited.
Key Financial Metrics and Transaction Terms
This filing details a strategic alliance rather than standard periodic financial results. Key financial terms include:
- Up-Front Payment: $90.0 million payable by Allergan to Editas upon entering the agreement.
- Regulatory Milestone (LCA10 Program): A one-time payment in the low-eight digits upon acceptance of an investigational new drug application (IND) submission.
- Option Exercise Fees:
- Initial exercise: Low-eight digits.
- Extended period exercise: Higher low-eight digits plus specified costs.
- End-of-term exercise (undelivered programs): Low-seven digits.
- Extension Fees: Mid-seven digits for extending the option period.
- Milestone Payments:
- Clinical, regulatory, and launch milestones: Up to a low-nine-digit amount in aggregate per program.
- Commercial milestones: Up to a high-eight-digit amount in aggregate per program.
- Total potential milestones per indication: Could exceed $200 million.
- Royalties: High-single digit percentages on net sales of Licensed Products.
- Profit Sharing (Optional): For the LCA10 Program and one other, Editas may elect to share net profits/losses equally in the U.S. in lieu of royalties, subject to reimbursing half of Allergan's development costs.
Material Changes and Operational Impact
Strategic Shift: Editas has entered a seven-year research term (extendable by up to three years) to develop up to five Collaboration Development Programs for ocular disorders, including the Leber's Congenital Amaurosis type 10 (LCA10) program.
Exclusivity and Restrictions:
- During the research term, Editas is restricted from developing, manufacturing, or commercializing gene editing therapies in the ocular field (subject to exceptions).
- Allergan holds an exclusive option to license up to five programs.
- Editas retains sole responsibility for development costs prior to option exercise.
Guidance, Risks, and Contingencies
Management Commentary: The agreement establishes an Alliance Steering Committee (ASC) with equal representation to oversee target selection and criteria satisfaction. Decisions are made by consensus.
Risks and Contingencies:
- Termination Rights: Allergan may terminate the agreement for uncured material breach or for any reason on a program-by-program basis (with 90 days' notice) after exercising an option.
- Change of Control: Allergan may terminate the research term if Editas undergoes a change of control, though no options may be exercised following such termination.
- Performance Obligation: The research term automatically extends if Editas fails to deliver five Option Packages meeting specified criteria.
- Upstream Obligations: Editas remains obligated to pay license fees, milestones, and royalties to its upstream licensors based on Allergan's exercise of rights.
Investor Verification Checklist
- Verify the exact dollar amounts for "low-eight digit," "mid-seven digit," and "low-nine digit" payments in subsequent financial statements or press releases.
- Confirm the specific criteria for the "Option Package" delivery to understand the risk of research term extension.
- Monitor the status of the LCA10 Program IND submission to trigger the low-eight digit regulatory payment.
- Review Editas's cash burn rate to assess if the $90 million up-front payment significantly alters liquidity or runway.
- Check for any upstream licensing agreements that may require Editas to share a portion of the $90 million or future milestones with third parties.